Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZX2GE)

Drug Name

2-(3-guanidinophenyl)-3-mercaptopropanoic acid Drug Info

Synonyms

2-(3-GUANIDINOPHENYL)-3-MERCAPTOPROPANOIC ACID; (2R)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-SULFANYLPROPANOIC ACID; L98; AC1NA0C3; ZINC16051731; DB04723; (2R)-2-(3-carbamimidamidophenyl)-3-sulfanylpropanoic acid; (2R)-2-[3-(diaminomethylideneamino)phenyl]-3-sulfanylpropanoic acid; (2R)-2-{3-[(diaminomethylidene)amino]phenyl}-3-sulfanylpropanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 4369579
TTD Drug ID: DMZX2GE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Carboxypeptidase B2 (CPB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR-126119	DMKHM7O	Cerebrovascular ischaemia	8B1Z	Phase 1	[2]
UK-396082	DMFYKDX	Thrombosis	DB61-GB90	Phase 1	[3]
DS-1040	DMXCN37	Ischemic stroke	8B11.5Z	Phase 1	[4]
SAR-104772	DMQ9ZY0	Cerebrovascular ischaemia	8B1Z	Phase 1	[5]
AZD-9684	DMHA5ME	Thrombosis	DB61-GB90	Discontinued in Phase 2	[6]
PMID14640538C3	DMR2L6X	Discovery agent	N.A.	Investigative	[7]
DL-benzylsuccinic acid	DMHI9ZJ	Discovery agent	N.A.	Investigative	[8]
PMID19954973C4	DMDYZE5	Discovery agent	N.A.	Investigative	[3]
3-mercapto-2-(piperidin-3-yl)propanoic acid	DMPJBNC	Discovery agent	N.A.	Investigative	[1]
6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid	DMMUE05	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carboxypeptidase B2 (CPB2)	TTP18AY	CBPB2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
2	TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6.
3	Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
4	Clinical pipeline report, company report or official report of Daiichi Sankyo.
5	Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009.
6	Clinical pipeline report, company report or official report of AstraZeneca.
7	Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
8	A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
9	Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5.